JP2014507484A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014507484A5 JP2014507484A5 JP2013557930A JP2013557930A JP2014507484A5 JP 2014507484 A5 JP2014507484 A5 JP 2014507484A5 JP 2013557930 A JP2013557930 A JP 2013557930A JP 2013557930 A JP2013557930 A JP 2013557930A JP 2014507484 A5 JP2014507484 A5 JP 2014507484A5
- Authority
- JP
- Japan
- Prior art keywords
- solution
- buffer
- glucagon
- formulation
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 149
- 239000000872 buffer Substances 0.000 claims description 72
- 238000000034 method Methods 0.000 claims description 40
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 38
- 102000051325 Glucagon Human genes 0.000 claims description 35
- 108060003199 Glucagon Proteins 0.000 claims description 35
- 229960004666 glucagon Drugs 0.000 claims description 35
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 35
- 239000002798 polar solvent Substances 0.000 claims description 35
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 24
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 17
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 16
- 230000000087 stabilizing effect Effects 0.000 claims description 16
- 239000006184 cosolvent Substances 0.000 claims description 14
- 239000004471 Glycine Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 229920002472 Starch Polymers 0.000 claims description 10
- 235000014633 carbohydrates Nutrition 0.000 claims description 10
- 239000007979 citrate buffer Substances 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 239000008363 phosphate buffer Substances 0.000 claims description 10
- 235000019698 starch Nutrition 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 7
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 7
- 230000008014 freezing Effects 0.000 claims description 6
- 238000007710 freezing Methods 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- 208000013016 Hypoglycemia Diseases 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 3
- 125000000647 trehalose group Chemical group 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims 6
- 239000000010 aprotic solvent Substances 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 104
- 108090000765 processed proteins & peptides Proteins 0.000 description 95
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 28
- 239000000843 powder Substances 0.000 description 16
- 102000004877 Insulin Human genes 0.000 description 14
- 108090001061 Insulin Proteins 0.000 description 14
- 229940125396 insulin Drugs 0.000 description 14
- 229960003611 pramlintide Drugs 0.000 description 14
- 108010029667 pramlintide Proteins 0.000 description 14
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 14
- 102000003982 Parathyroid hormone Human genes 0.000 description 10
- 108090000445 Parathyroid hormone Proteins 0.000 description 10
- 239000000199 parathyroid hormone Substances 0.000 description 10
- 229960001319 parathyroid hormone Drugs 0.000 description 10
- YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 description 6
- 108010011459 Exenatide Proteins 0.000 description 6
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 6
- 108010072051 Glatiramer Acetate Proteins 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 229960001519 exenatide Drugs 0.000 description 6
- 229940042385 glatiramer Drugs 0.000 description 6
- 108030001720 Bontoxilysin Proteins 0.000 description 5
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 5
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 5
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 5
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 5
- 108010000817 Leuprolide Proteins 0.000 description 5
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 5
- 102000013275 Somatomedins Human genes 0.000 description 5
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 5
- -1 analogs thereof Substances 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 229940053031 botulinum toxin Drugs 0.000 description 5
- 125000000837 carbohydrate group Chemical group 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 5
- 108010013846 hematide Proteins 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 5
- 229960004338 leuprorelin Drugs 0.000 description 5
- 108050003126 conotoxin Proteins 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 101800001982 Cholecystokinin Proteins 0.000 description 3
- 102100025841 Cholecystokinin Human genes 0.000 description 3
- 108010051696 Growth Hormone Proteins 0.000 description 3
- 102000018997 Growth Hormone Human genes 0.000 description 3
- 229940107137 cholecystokinin Drugs 0.000 description 3
- 239000000122 growth hormone Substances 0.000 description 3
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 2
- 101710142969 Somatoliberin Proteins 0.000 description 2
- 102100022831 Somatoliberin Human genes 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 2
- 229940050526 hydroxyethylstarch Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161451568P | 2011-03-10 | 2011-03-10 | |
| US61/451,568 | 2011-03-10 | ||
| US201161478692P | 2011-04-25 | 2011-04-25 | |
| US61/478,692 | 2011-04-25 | ||
| US201161553388P | 2011-10-31 | 2011-10-31 | |
| US61/553,388 | 2011-10-31 | ||
| US201261609123P | 2012-03-09 | 2012-03-09 | |
| US61/609,123 | 2012-03-09 | ||
| PCT/US2012/028621 WO2012122535A2 (en) | 2011-03-10 | 2012-03-09 | Stable formulations for parenteral injection of peptide drugs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014507484A JP2014507484A (ja) | 2014-03-27 |
| JP2014507484A5 true JP2014507484A5 (enExample) | 2014-05-08 |
| JP6063877B2 JP6063877B2 (ja) | 2017-01-18 |
Family
ID=45894671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013557930A Active JP6063877B2 (ja) | 2011-03-10 | 2012-03-09 | ペプチド薬物の非経口注射用の安定な製剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (6) | US8697644B2 (enExample) |
| EP (1) | EP2683364B1 (enExample) |
| JP (1) | JP6063877B2 (enExample) |
| KR (1) | KR101978527B1 (enExample) |
| CN (2) | CN105853348B (enExample) |
| AU (2) | AU2012225268B2 (enExample) |
| BR (1) | BR112013023062B1 (enExample) |
| CA (1) | CA2829400C (enExample) |
| DK (1) | DK2683364T3 (enExample) |
| EA (1) | EA028572B1 (enExample) |
| ES (1) | ES2621304T3 (enExample) |
| IL (1) | IL228348A0 (enExample) |
| MX (1) | MX342675B (enExample) |
| SG (1) | SG193389A1 (enExample) |
| WO (1) | WO2012122535A2 (enExample) |
| ZA (1) | ZA201306836B (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105853348B (zh) | 2011-03-10 | 2019-08-30 | Xeris药物公司 | 肠胃外注射用稳定溶液 |
| ES2574761T3 (es) * | 2011-10-31 | 2016-06-21 | Xeris Pharmaceuticals, Inc. | Formulaciones para el tratamiento de la diabetes |
| US9125805B2 (en) | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| JP2016506401A (ja) | 2012-12-21 | 2016-03-03 | サノフイ | 二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体 |
| US9018162B2 (en) | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
| WO2014124096A1 (en) * | 2013-02-06 | 2014-08-14 | Perosphere Inc. | Stable glucagon formulations |
| US8871713B2 (en) | 2013-03-01 | 2014-10-28 | Theratechnologies Inc. | Formulations of growth hormone releasing factor (GRF) molecules with improved stability |
| US12239822B2 (en) | 2013-03-15 | 2025-03-04 | Windgap Medical, Inc. | Portable drug mixing and delivery device and associated methods |
| KR20140123782A (ko) * | 2013-04-15 | 2014-10-23 | 에스케이케미칼주식회사 | 카스포펀진 및 완충제를 포함하는 안정성이 개선된 약학적 조성물 |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／ｇｉｐ受體促效劑 |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| EP3082419A4 (en) | 2013-12-18 | 2017-09-20 | Windgap Medical, Inc. | Drug mixing and delivery system and method |
| US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
| EP3102184B1 (en) * | 2014-02-06 | 2019-01-30 | Xeris Pharmaceuticals, Inc. | Stable peptide formulations and methods for preparation |
| WO2015153728A1 (en) | 2014-04-02 | 2015-10-08 | Xeris Pharmaceuticals, Inc. | Polar aprotic solvent-compatible infusion sets, components, and methods |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| US20160015890A1 (en) * | 2014-06-09 | 2016-01-21 | Artificial Pancreas Technologies, Inc. | System and method of variable dose glucagon delivery |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| US20160074515A1 (en) | 2014-06-20 | 2016-03-17 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
| AU2015300944B2 (en) | 2014-08-06 | 2019-07-11 | Xeris Pharmaceuticals, Inc. | Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes |
| CN107106659B (zh) * | 2014-10-27 | 2022-07-08 | 莱迪杜德制药公司 | 肠胃外胰高血糖素制剂 |
| CA2971440C (en) | 2014-12-18 | 2024-02-13 | Windgap Medical, Inc. | Method and compositions for dissolving or solubilizing therapeutic agents |
| WO2016196976A1 (en) * | 2015-06-04 | 2016-12-08 | Xeris Pharmaceuticals, Inc. | Glucagon delivery apparatuses and related methods |
| US9649364B2 (en) | 2015-09-25 | 2017-05-16 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| US20190083578A1 (en) * | 2015-06-10 | 2019-03-21 | Xeris Pharmaceuticals, Inc. | Use of low dose glucagon |
| EP3307295A1 (en) * | 2015-06-10 | 2018-04-18 | Xeris Pharmaceuticals, Inc. | Use of low dose glucagon |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| CA2995392C (en) * | 2015-09-04 | 2023-08-15 | Hailiang Chen | Stabilized glucagon solutions |
| US11590205B2 (en) | 2015-09-25 | 2023-02-28 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
| WO2017075535A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
| US11074992B2 (en) | 2016-04-12 | 2021-07-27 | Andrew Ka-Ching WONG | Method for determining interaction sites between biosequences |
| CN117018170A (zh) * | 2016-06-20 | 2023-11-10 | Isa制药有限公司 | 肽疫苗制剂 |
| IL265109B2 (en) * | 2016-09-13 | 2024-05-01 | Allergan Inc | Stabilized non-protein clostridial toxin compositions |
| ES2944544T3 (es) * | 2017-02-03 | 2023-06-22 | Univ Vanderbilt | Sistemas, composiciones y métodos para el tratamiento de la diabetes |
| BR112019024987A2 (pt) | 2017-06-02 | 2020-06-16 | Xeris Pharmaceuticals, Inc. | Formulações de fármaco de molécula pequena resistente à precipitação |
| US20210137809A1 (en) * | 2017-06-14 | 2021-05-13 | Biosolution Co., Ltd | Cosmetic composition for wrinkle reduction or anti-inflammation, containing substance p |
| CA3167644A1 (en) | 2017-09-22 | 2019-03-28 | Asahi Kasei Pharma Corporation | Teriparatide-containing liquid pharmaceutical composition having excellent pharmacokinetics and/or safety |
| US20200289621A1 (en) | 2017-09-22 | 2020-09-17 | Asahi Kasei Pharma Corporation | Teriparatide-containing liquid pharmaceutical composition having excellent stability |
| WO2019126753A1 (en) | 2017-12-22 | 2019-06-27 | Xeris Pharmaceuticals, Inc. | Treatment of exercise-induced hypoglycemia in type 1 and insulin using type 2 diabetes |
| US20210030847A1 (en) * | 2018-01-23 | 2021-02-04 | Xeris Pharmaceuticals, Inc. | Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon |
| EP3761962A4 (en) * | 2018-03-07 | 2021-12-15 | ReForm Biologics, Inc. | EXCIPIENT COMPOUNDS FOR PROTEIN-BASED FORMULATIONS |
| IL281393B2 (en) | 2018-09-14 | 2025-02-01 | Cara Therapeutics Inc | Oral formulations of kappa opioid receptor agonists |
| CN109485712A (zh) * | 2018-11-23 | 2019-03-19 | 中国海洋大学 | 二聚体Vc1.1-dimer，RgIA-dimer和PeIA-dimer |
| US10987458B2 (en) * | 2018-12-21 | 2021-04-27 | Fresenius Medical Care Holdings, Inc. | Method of using a medical fluid generating machine |
| AU2020219125B2 (en) | 2019-02-05 | 2025-10-02 | Lindy Biosciences, Inc. | Isolated cell culture components and methods for isolating the same from liquid cell culture medium |
| JP2022543956A (ja) * | 2019-05-07 | 2022-10-17 | フロンティア バイオテクノロジーズ インク． | 安定なアルブビルチド組成物 |
| EP3975993A1 (en) | 2019-05-31 | 2022-04-06 | Xeris Pharmaceuticals, Inc. | Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same |
| AU2021236662A1 (en) | 2020-03-18 | 2022-11-10 | Cara Therapeutics, Inc. | Oligosaccharide formulations of kappa opioid receptor agonists |
| EP4164675A4 (en) * | 2020-06-11 | 2024-06-26 | Abvance Therapeutics Inc. | SYSTEMS, DEVICES, COMPOSITIONS AND METHODS FOR TREATING DIABETES |
| KR20230026984A (ko) | 2020-06-26 | 2023-02-27 | 엑스에리스 파머수티클스, 인크. | 비양성자성의 극성 용매 중의 안정한 지속 방출성 치료 조성물 및 그의 제조 방법 |
| WO2024011185A1 (en) * | 2022-07-07 | 2024-01-11 | Serán BioScience, LLC | Methods and systems for use of low-volatility solvents for spray drying |
| US20240148678A1 (en) | 2022-10-19 | 2024-05-09 | Xeris Pharmaceuticals, Inc. | Sustained release injectable therapeutic formulations using aprotic polar solvents |
| EP4604922A1 (en) | 2022-10-19 | 2025-08-27 | Xeris Pharmaceuticals, Inc. | Stable levothyroxine compositions in aprotic polar solvents |
Family Cites Families (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3016895A (en) | 1958-08-01 | 1962-01-16 | Pan American Lab Inc | Injector for subcutaneous implantation of solids |
| US5260306A (en) | 1981-07-24 | 1993-11-09 | Fisons Plc | Inhalation pharmaceuticals |
| GB2119248A (en) * | 1982-04-28 | 1983-11-16 | John Kenneth Mcmullen | Insulin formulations and method of producing them |
| CH664005A5 (de) | 1984-05-19 | 1988-01-29 | Glatt Maschinen & Apparatebau | Verfahren zum trocknen eines teilchenfoermigen gutes und einrichtung zur durchfuehrung des verfahrens. |
| US5124317A (en) | 1985-08-02 | 1992-06-23 | Farmitalia Carlo Erba S.P.A. | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| US5977082A (en) | 1985-08-02 | 1999-11-02 | Pharmacia & Upjohn Company | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| US4927571A (en) | 1987-05-18 | 1990-05-22 | Liposome Technology, Inc. | Preparation of injectable doxorubicin/liposome suspension |
| US4848094A (en) | 1988-04-29 | 1989-07-18 | Union Carbide Corporation | Droplet freezing method and apparatus |
| US5031336A (en) | 1989-08-31 | 1991-07-16 | Abbott Laboratories | Lyophilization of bulk pharmaceuticals |
| US5092843A (en) | 1990-04-12 | 1992-03-03 | Survival Technology, Inc. | Dispersion multichamber auto-injector |
| CA2081474A1 (en) | 1990-05-08 | 1991-11-09 | Manzer Durrani | Direct spray-dried drug/lipid powder composition |
| AU7880991A (en) | 1990-05-10 | 1991-11-27 | Novo Nordisk A/S | A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols |
| US5208998A (en) | 1991-02-25 | 1993-05-11 | Oyler Jr James R | Liquid substances freeze-drying systems and methods |
| JP3277342B2 (ja) | 1992-09-02 | 2002-04-22 | 武田薬品工業株式会社 | 徐放性マイクロカプセルの製造法 |
| EP0625917B1 (fr) | 1992-12-15 | 1998-03-25 | Sanofi | Dispositif pour la preparation d'une solution, d'une suspension ou d'une emulsion d'une substance medicinale |
| US5496801A (en) * | 1993-12-23 | 1996-03-05 | Allelix Biopharmaceuticals Inc. | Parathyroid hormone formulation |
| US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| US5652216A (en) | 1994-05-26 | 1997-07-29 | Novo Nordisk A/S | Pharmaceutical preparation |
| US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
| KR970705979A (ko) | 1994-09-29 | 1997-11-03 | 디 히스 | 치료용 매개체로서의 분무-건조 미소입자 (Spray-dried microparticles as therapeutic vehicles) |
| US5932547A (en) | 1996-07-03 | 1999-08-03 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
| US5945128A (en) | 1996-09-04 | 1999-08-31 | Romano Deghenghi | Process to manufacture implants containing bioactive peptides |
| IN184589B (enExample) | 1996-10-16 | 2000-09-09 | Alza Corp | |
| JP2002512597A (ja) | 1996-12-20 | 2002-04-23 | アルザ コーポレイション | 注射可能な貯留槽ゲル組成物およびこの組成物の製造方法 |
| AU5806998A (en) | 1996-12-31 | 1998-07-31 | Inhale Therapeutic Systems | Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes |
| DK0916347T3 (da) | 1997-11-18 | 2003-04-22 | Uni Pharma Kleon Tsetis A B E | Farmaceutiske injicerbare opløsninger der indeholder paracetamol og kombinationer af paracetamol med andre aktive bestanddele |
| FR2783433B1 (fr) | 1998-09-18 | 2001-02-16 | Delab | Seringues pour l'administration de formulations pateuses ou semi-solides |
| SE9803662D0 (sv) | 1998-10-26 | 1998-10-26 | Pharmacia & Upjohn Ab | Autoinjector |
| US6199297B1 (en) | 1999-02-01 | 2001-03-13 | Integrated Biosystems, Inc. | Lyophilization apparatus and methods |
| US7919109B2 (en) | 1999-02-08 | 2011-04-05 | Intarcia Therapeutics, Inc. | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
| US6253463B1 (en) | 1999-04-26 | 2001-07-03 | Niro A/S | Method of spray drying |
| US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| US7582311B1 (en) | 1999-10-15 | 2009-09-01 | Genentech, Inc. | Injection vehicle for polymer-based formulations |
| US7651703B2 (en) | 1999-10-15 | 2010-01-26 | Genentech, Inc. | Injection vehicle for polymer-based formulations |
| US6478776B1 (en) | 2000-04-05 | 2002-11-12 | Biocardia, Inc. | Implant delivery catheter system and methods for its use |
| WO2001078687A1 (en) | 2000-04-18 | 2001-10-25 | Peptron Inc. | Injectable sustained release pharmaceutical composition and processes for preparing the same |
| US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
| CN1283215C (zh) | 2000-06-28 | 2006-11-08 | A·J·舒克拉 | 生物活性物质的可生物降解载体和释放系统 |
| CA2419067C (en) | 2000-08-18 | 2008-12-23 | Takeda Chemical Industries, Ltd. | Injectable composition comprising benzimidazole compound and strong alkali |
| RO120121B1 (ro) | 2000-12-18 | 2005-09-30 | Elena Ionaşcu | Soluţie injectabilă, cu efect antiinflamator, procedeu de obţinere şi metodă de tratament a bolilor autoimune |
| WO2002070399A1 (en) | 2001-03-06 | 2002-09-12 | Texas Research International, Inc. | A chemically and biologically resistant hydration system |
| US6887462B2 (en) * | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
| US6676958B2 (en) | 2001-06-19 | 2004-01-13 | Advanced Bioadjuvants, Llc | Adjuvant composition for mucosal and injection delivered vaccines |
| JP4490095B2 (ja) | 2001-06-29 | 2010-06-23 | メドグラフト マイクロテック インコーポレイテッド | 生体分解性の注入可能な移植物およびそれに関連する製造方法ならびに使用方法 |
| EP1413310A1 (en) | 2001-07-09 | 2004-04-28 | Yamanouchi Pharmaceutical Co. Ltd. | Sustained-release compositions for injection and process for producing the same |
| US6733813B2 (en) | 2001-08-02 | 2004-05-11 | Ocean Spray Cranberries, Inc. | Process for producing acids-enriched juice and acids-reduced juice |
| CA2466632C (en) | 2001-11-14 | 2014-02-11 | Alza Corporation | Injectable depot compositions and uses thereof |
| DE10161077A1 (de) | 2001-12-12 | 2003-06-18 | Boehringer Ingelheim Vetmed | Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion |
| CN1582170B (zh) | 2001-12-18 | 2010-05-05 | 联合制药克伦茨蒂斯药物实验室公司 | 扑热息痛的肠胃外组合物 |
| CN1171610C (zh) | 2002-04-23 | 2004-10-20 | 张瑞香 | 一种治疗心脑血管和眼底病的中药针剂及其制备方法 |
| US8871241B2 (en) | 2002-05-07 | 2014-10-28 | Psivida Us, Inc. | Injectable sustained release delivery devices |
| DE60327936D1 (de) | 2002-10-17 | 2009-07-23 | Univ British Columbia | Modulatoren von ship-1 |
| EP1558234B1 (en) | 2002-10-25 | 2007-05-23 | Dompé S.P.A. | Painless injectable compositions containing salt of 2-arylpropionic acids |
| CN102205127A (zh) | 2002-12-18 | 2011-10-05 | 阿尔乔医疗公司 | 类辣椒素的给药 |
| CN1507858A (zh) | 2002-12-19 | 2004-06-30 | 王玉万 | 含氟化氯霉素的兽用液体制剂 |
| WO2004057959A2 (en) * | 2002-12-20 | 2004-07-15 | Generipharm, Inc. | Intracutaneous injection |
| WO2004089985A1 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Stable pharmaceutical compositions |
| ES2298672T3 (es) | 2003-04-14 | 2008-05-16 | Wyeth Holdings Corporation | Composiciones que contienen piperacilina y tazobactam utiles para inyeccion. |
| WO2004098643A1 (en) | 2003-04-14 | 2004-11-18 | Wyeth Holdings Corporation | Compositions containing piperacillin and tazobactam useful for injection |
| KR100517643B1 (ko) | 2003-07-25 | 2005-09-28 | 한국과학기술연구원 | 온도 감응성 폴리포스파젠계 고분자, 이의 제조방법 및이를 이용한 주입형 온도 감응성 폴리포스파젠 하이드로젤 |
| US20050100538A1 (en) | 2003-07-31 | 2005-05-12 | Attawia Mohamed | Intradiscal injection of anti-oxidants |
| SI1502589T1 (sl) | 2003-07-31 | 2006-12-31 | Emdoka Bvba Drug Registration | Veterinarske vodne injektibilne suspenzije, ki vsebujejo florfenikol |
| PL1658171T3 (pl) | 2003-08-22 | 2008-10-31 | Singulus Tech Ag | Sposób łączenia substratów do wytwarzania dysków optycznych, oraz urządzenie do realizacji tego sposobu |
| US20050069591A1 (en) | 2003-09-30 | 2005-03-31 | Howard Bernstein | Injectable, oral, or topical sustained release pharmaceutical formulations |
| US20050118206A1 (en) * | 2003-11-14 | 2005-06-02 | Luk Andrew S. | Surfactant-based gel as an injectable, sustained drug delivery vehicle |
| US20080248999A1 (en) | 2007-04-04 | 2008-10-09 | Biodel Inc. | Amylin formulations |
| EP1987843A3 (en) * | 2004-03-12 | 2011-10-26 | Intercell AG | Method for solubilising peptide mixtures |
| US20050240166A1 (en) | 2004-04-26 | 2005-10-27 | Microsolutions, Inc. | Implantable device, formulation and method for anti-psychotic therapy using risperidone |
| EP1753404A1 (en) | 2004-05-12 | 2007-02-21 | Baxter International Inc. | Microspheres comprising protein and showing injectability at high concentrations of said agent |
| US20060160823A1 (en) | 2004-05-28 | 2006-07-20 | Leonore Witchey-Lakshmanan | Particulate-stabilized injectable pharmaceutical compositions of Posaconazole |
| CN101056643A (zh) | 2004-09-13 | 2007-10-17 | Pr药品有限公司 | 雌二醇代谢物的长效可注射晶体制剂及其应用方法 |
| JP5069130B2 (ja) | 2005-01-27 | 2012-11-07 | エリモス・ファーマスーティカルズ・エルエルシー | Ｎｄｇａ化合物を包含するカテコールブタンの送達のための経口用製剤 |
| EP1909824B1 (en) * | 2005-04-08 | 2011-05-18 | Amylin Pharmaceuticals, Inc. | Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent |
| US20080305161A1 (en) | 2005-04-13 | 2008-12-11 | Pfizer Inc | Injectable depot formulations and methods for providing sustained release of nanoparticle compositions |
| BRPI0609191B8 (pt) | 2005-06-17 | 2021-05-25 | Ligand Pharm Inc | métodos e compostos moduladores de receptor de androgênio |
| US8435224B2 (en) | 2005-09-12 | 2013-05-07 | Abela Pharmaceuticals, Inc. | Materials for facilitating administration of dimethyl sulfoxide (DMSO) and related compounds |
| AU2007207618B2 (en) | 2006-01-18 | 2011-03-24 | Foresee Pharmaceuticals Co., Ltd. | Pharmaceutical compositions with enhanced stability |
| AR054215A1 (es) | 2006-01-20 | 2007-06-13 | Eriochem Sa | Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit |
| US20090143737A1 (en) | 2006-05-17 | 2009-06-04 | Terumo Kabushiki Kaisha, | Indwelling needle assembly |
| US20070275030A1 (en) | 2006-05-25 | 2007-11-29 | The General Hospital Corporation Dba Massachusetts General Hospital | Anti-cross-linking agents and methods for inhibiting cross-linking of injectable hydrogel formulations |
| CA2662827C (en) | 2006-09-07 | 2015-04-07 | Merial Limited | Soft chewable, tablet, and long-acting injectable veterinary antibiotic formulations |
| CA2665101A1 (en) | 2006-10-05 | 2008-04-10 | Panacea Biotec Ltd. | Injectable depot composition and it's process of preparation |
| WO2008098212A2 (en) | 2007-02-08 | 2008-08-14 | Diobex, Inc. | Extended release formulations of glucagon and other peptides and proteins |
| CA2683610C (en) * | 2007-04-23 | 2013-01-08 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
| JP5496082B2 (ja) | 2007-04-30 | 2014-05-21 | ノボ・ノルデイスク・エー／エス | タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物 |
| EP2152243A2 (en) | 2007-04-30 | 2010-02-17 | Novo Nordisk A/S | Highly concentrated insulin solutions and compositions |
| TW200922635A (en) | 2007-08-31 | 2009-06-01 | Archimedes Dev Ltd | Non-aqueous pharmaceutical compositions |
| US20090088393A1 (en) | 2007-09-28 | 2009-04-02 | Zomanex, Llc | Methods and formulations for converting intravenous and injectable drugs into oral dosage forms |
| CL2008003305A1 (es) | 2007-11-06 | 2009-06-05 | M/S Panacea Biotec Ltd | Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer. |
| EP2060268A1 (en) * | 2007-11-15 | 2009-05-20 | Novo Nordisk A/S | Pharmaceutical compositions for pulmonary or nasal delivery of peptides |
| CN101877963A (zh) | 2007-11-28 | 2010-11-03 | 泰华制药工业有限公司 | 延缓临床确诊的多发性硬化症发作的方法 |
| JP5539221B2 (ja) | 2007-12-21 | 2014-07-02 | リガンド・ファーマシューティカルズ・インコーポレイテッド | 選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）およびその使用 |
| EP2249809A1 (en) * | 2008-01-15 | 2010-11-17 | Abbott GmbH & Co. KG | Powdered protein compositions and methods of making same |
| KR101517415B1 (ko) | 2008-05-14 | 2015-05-07 | 에스케이바이오팜 주식회사 | 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물 |
| MX2011000795A (es) | 2008-07-23 | 2011-03-29 | Bharat Serums & Vaccines Ltd | Nanoemulsion estable inyectable de docetaxel de aceite en agua. |
| GB0815435D0 (en) | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
| JP5618440B2 (ja) | 2008-08-25 | 2014-11-05 | 電気化学工業株式会社 | 注射器 |
| WO2010036702A1 (en) | 2008-09-25 | 2010-04-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
| US20110118578A1 (en) | 2009-11-17 | 2011-05-19 | Roche Diagnostics Operations, Inc. | Hypoglycemic treatment methods and systems |
| US20110223208A1 (en) | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| GB2481017B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| WO2012012460A1 (en) * | 2010-07-19 | 2012-01-26 | Xeris Pharmaceuticals, Inc. | Stable glucagon formulations for the treatment of hypoglycemia |
| JP5632226B2 (ja) | 2010-07-30 | 2014-11-26 | 株式会社細川洋行 | 医療用多層チューブ、および医療用輸液バッグ |
| CN105853348B (zh) * | 2011-03-10 | 2019-08-30 | Xeris药物公司 | 肠胃外注射用稳定溶液 |
| ES2574761T3 (es) * | 2011-10-31 | 2016-06-21 | Xeris Pharmaceuticals, Inc. | Formulaciones para el tratamiento de la diabetes |
| PL2849723T3 (pl) | 2012-05-18 | 2018-10-31 | Genentech, Inc. | Formulacje o wysokim stężeniu przeciwciał monoklonalnych |
| US9522235B2 (en) | 2012-05-22 | 2016-12-20 | Kaleo, Inc. | Devices and methods for delivering medicaments from a multi-chamber container |
| US9125805B2 (en) | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
| AU2013308693A1 (en) | 2012-08-29 | 2015-03-12 | Mannkind Corporation | Method and composition for treating hyperglycemia |
| US9018162B2 (en) * | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
| EP3102184B1 (en) | 2014-02-06 | 2019-01-30 | Xeris Pharmaceuticals, Inc. | Stable peptide formulations and methods for preparation |
| WO2015153728A1 (en) | 2014-04-02 | 2015-10-08 | Xeris Pharmaceuticals, Inc. | Polar aprotic solvent-compatible infusion sets, components, and methods |
| AU2015300944B2 (en) | 2014-08-06 | 2019-07-11 | Xeris Pharmaceuticals, Inc. | Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes |
| WO2016196976A1 (en) | 2015-06-04 | 2016-12-08 | Xeris Pharmaceuticals, Inc. | Glucagon delivery apparatuses and related methods |
| EP3307295A1 (en) | 2015-06-10 | 2018-04-18 | Xeris Pharmaceuticals, Inc. | Use of low dose glucagon |
-
2012
- 2012-03-09 CN CN201610221799.6A patent/CN105853348B/zh active Active
- 2012-03-09 BR BR112013023062-2A patent/BR112013023062B1/pt active IP Right Grant
- 2012-03-09 AU AU2012225268A patent/AU2012225268B2/en active Active
- 2012-03-09 EP EP12711071.6A patent/EP2683364B1/en active Active
- 2012-03-09 WO PCT/US2012/028621 patent/WO2012122535A2/en not_active Ceased
- 2012-03-09 EA EA201370178A patent/EA028572B1/ru not_active IP Right Cessation
- 2012-03-09 CA CA2829400A patent/CA2829400C/en active Active
- 2012-03-09 MX MX2013010376A patent/MX342675B/es active IP Right Grant
- 2012-03-09 US US13/417,073 patent/US8697644B2/en active Active
- 2012-03-09 SG SG2013068093A patent/SG193389A1/en unknown
- 2012-03-09 CN CN201280012645.6A patent/CN103442695B/zh active Active
- 2012-03-09 DK DK12711071.6T patent/DK2683364T3/en active
- 2012-03-09 ES ES12711071.6T patent/ES2621304T3/es active Active
- 2012-03-09 KR KR1020137026683A patent/KR101978527B1/ko active Active
- 2012-03-09 JP JP2013557930A patent/JP6063877B2/ja active Active
-
2013
- 2013-09-11 IL IL228348A patent/IL228348A0/en active IP Right Grant
- 2013-09-11 ZA ZA2013/06836A patent/ZA201306836B/en unknown
-
2014
- 2014-02-24 US US14/188,464 patent/US9302010B2/en active Active
- 2014-02-27 US US14/192,679 patent/US9295724B2/en active Active
- 2014-02-27 US US14/192,697 patent/US9339545B2/en active Active
-
2016
- 2016-03-22 US US15/077,633 patent/US10987399B2/en active Active
-
2017
- 2017-01-17 AU AU2017200295A patent/AU2017200295B2/en active Active
-
2021
- 2021-03-29 US US17/215,449 patent/US20210315961A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6763777B2 (ja) | 安定なペプチド製剤、および調製のための方法 | |
| US20210315961A1 (en) | Stable formulations for parenteral injection of peptide drugs | |
| JP2017505331A5 (enExample) | ||
| JP6835831B2 (ja) | 非プロトン性極性溶媒中の安定な治療用グルカゴン製剤を製造するための方法 | |
| WO2014124151A1 (en) | Methods for rapidly treating severe hypoglycemia | |
| JP2018528242A5 (enExample) | ||
| CN101912600A (zh) | 改善胰岛素在溶液中稳定性的方法 | |
| JP2021511386A5 (enExample) | ||
| CN120076788A (zh) | 在非质子极性溶剂中的稳定的左甲状腺素组合物 | |
| CN120152698A (zh) | 使用非质子极性溶剂的缓释可注射制剂 | |
| EP3225235B1 (en) | Stable peptide formulations for parenteral injection | |
| HK1245089B (en) | Stable peptide formulations for parenteral injection | |
| HK1191230B (en) | Stable formulations for parenteral injection of peptide drugs |